LIQUIDIA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.79 USD | -1.46% |
|
+2.08% | +6.32% |
| 04-01 | Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension | MT |
| 04-01 | Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling | DJ |
Chart calendar Liquidia Corporation
960e75525efcfc4925e1cfb2e9c683._Zxaos2L7ENqN_aBrhKxpJdyLdmeAzROsG2uykpzpWk.pK80x6bpmCZYD7HE_nvl4-QURJrEMEU-8SzqvRwq8xPE1jTtnc-0DiF-vw~cb125d861b498b73ea3a2a6c29f2cb07
Upcoming events on Liquidia Corporation
Past events on Liquidia Corporation
| 09/04/2024 18:30 | Needham Healthcare Conference |
| 13/03/2024 12:30 | Q4 2023 Earnings Call |
| 13/03/2024 10:00 | Q4 2023 Earnings Release |
| 02/02/2024 16:20 | Pulmonary Vascular Research Institute Congress |
| 10/01/2024 19:15 | JPMorgan Healthcare Conference |
| 07/11/2023 13:30 | Q3 2023 Earnings Call |
| 07/11/2023 11:30 | Q3 2023 Earnings Release |
| 10/08/2023 13:30 | Q2 2023 Earnings Call |
| 10/08/2023 11:00 | Q2 2023 Earnings Release |
| 28/06/2023 13:30 | Liquidia Corporation and Pharmosa Biopharm L606 Licensing Agreement Call |
| 15/06/2023 21:30 | Annual General Meeting |
| 09/06/2023 14:30 | Jefferies Healthcare Conference |
| 22/05/2023 16:30 | Thoracic Society International Conference - Exploratory Efficacy Analysis of INSPIRE Open Label Exte |
| 09/05/2023 17:45 | Bank of America Healthcare Conference |
| 04/05/2023 13:30 | Q1 2023 Earnings Call |
| 04/05/2023 11:30 | Q1 2023 Earnings Release |
| 18/04/2023 16:00 | Needham Healthcare Conference - Fireside Chat |
| 16/03/2023 12:30 | Q4 2022 Earnings Call |
| 16/03/2023 10:30 | Q4 2022 Earnings Release |
| 08/11/2022 13:30 | Q3 2022 Earnings Call |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 8,07 8,07 0% | 0,74 0,00 - | 12,9 12,7 1.28% | 15,9 14,1 12.7% | 17,5 17,7 -1.16% | 63,9 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | -35,1 -42,0 16.39% | -71,2 -57,2 -24.59% | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -46,8 -46,4 -0.91% | -59,1 -57,5 -2.84% | -33,8 -29,2 -15.92% | -38,8 -42,3 8.26% | -73,4 -62,2 -18.03% | -78,2 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -47,6 -46,6 -2.21% | -59,8 -58,1 -2.79% | -34,6 -29,0 -19.24% | -41,0 -44,5 7.84% | -78,5 -66,9 -17.26% | -71,4 |
|
Net income Million USD | Released Forecast Spread | -47,6 -46,6 -2.21% | -59,8 -58,1 -2.79% | -34,6 -29,0 -19.24% | -41,0 -44,0 6.82% | -78,5 -66,9 -17.33% | -81,4 |
|
EPS USD | Released Forecast Spread | -2,59 -2,34 -10.68% | -1,76 -1,74 -1.29% | -0,70 -0,61 -15.7% | -0,67 -0,73 8.4% | -1,21 -1,02 -18.63% | -1,09 |
| Announcement Date | 11/03/20 | 23/03/21 | 17/03/22 | 16/03/23 | 13/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 3,22 3,05 5.54% | 3,49 3,34 4.5% | 3,92 3,53 10.94% | 3,17 3,33 -5.08% | 5,36 3,55 50.84% | 4,49 3,93 14.42% | 4,79 4,32 10.82% | 3,68 4,33 -15.13% | 4,53 4,73 -4.24% | 4,39 | 10,4 | 16,9 | 28,8 |
|
EBITDA Million USD | Released Forecast Spread | -3,42 -10,7 68.19% | ||||||||||||
|
EBIT Million USD | Released Forecast Spread | -11,4 -6,74 -68.65% | -14,5 -10,6 -36.16% | -8,97 -14,3 37.37% | -12,0 -10,3 -16.54% | -6,50 -9,81 33.78% | -9,23 -11,3 18.18% | -22,8 -10,6 -115.14% | -14,9 -13,7 -8.76% | -26,4 -15,1 -75.58% | -22,4 | -22,3 | -22,5 | -16,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -11,6 -6,02 -92.16% | -15,9 -10,7 -48.62% | -9,45 -14,6 35.51% | -9,09 -11,1 18.38% | -6,53 -10,7 39.06% | -11,7 -11,2 -5.18% | -23,5 -10,6 -121.43% | -15,8 -11,8 -34.22% | -27,5 -15,9 -72.29% | -21,7 | -21,7 | -19,9 | -12,6 |
|
Net income Million USD | Released Forecast Spread | -11,6 -6,02 -92.16% | -15,9 -10,7 -48.62% | -9,45 -14,6 35.51% | -9,09 -11,1 18.38% | -6,53 -10,1 35.21% | -11,7 -11,5 -2.15% | -23,5 -10,7 -119.53% | -15,8 -14,0 -13.09% | -27,5 -15,8 -73.91% | -22,7 | -22,6 | -22,8 | -16,8 |
|
EPS USD | Released Forecast Spread | -0,23 -0,12 -100% | -0,30 -0,21 -45.16% | -0,15 -0,25 40.59% | -0,14 -0,17 15.15% | -0,09 -0,16 42.2% | -0,18 -0,17 -3.85% | -0,36 -0,17 -116% | -0,24 -0,21 -12% | -0,42 -0,24 -78.19% | -0,30 | -0,30 | -0,30 | -0,22 |
| Announcement Date | 17/03/22 | 12/05/22 | 11/08/22 | 08/11/22 | 16/03/23 | 04/05/23 | 10/08/23 | 07/11/23 | 13/03/24 | - | - | - | - |
More events
Past sector events for Liquidia Corporation
| 03/05/2024 12:07 | AARTI DRUGS LIMITED: Q4 2024 Earnings Release |
| 03/05/2024 11:00 | AMNEAL PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 02/05/2024 | SCINOPHARM TAIWAN, LTD.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | DEVA HOLDING: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 21:01 | AMGEN INC.: Q1 2024 Earnings Release |
| 02/05/2024 18:43 | ALK-ABELLÓ A/S: Q1 2024 Earnings Release |
| 02/05/2024 12:30 | ORGANON & CO.: Q1 2024 Earnings Release |
| 02/05/2024 12:00 | BAUSCH HEALTH COMPANIES INC.: Q1 2024 Earnings Release |
| 02/05/2024 06:30 | NOVO NORDISK A/S: Q1 2024 Earnings Release |
| 01/05/2024 | GC BIOPHARMA CORP.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LQDA Stock
- Calendar Liquidia Corporation
